The COVID-19 crisis has significantly impacted physicians’ practices; but how and to what extent? Physicians have been managing significant workloads, while learning on the fly how to navigate and setup virtual meetings. Maintaining high levels of patient care while minimizing in-person interactions has also been challenging.
Strong online advertising and messaging are key to maximizing impact of any marketing campaign. With recent restrictions on in-person interactions, online advertising and messaging play an even greater role in reaching physicians. Our findings from a survey of n=227 Canadian physicians show that 82% of Canadian physicians have increased their use of online platforms as a result of COVID-19, 48% significantly so.
Physicians recognize that new medications often can be quite valuable for their patients and are eager to add them to their armamentarium. However, they do not always end up prescribing these new medications as much as they initially plan or as early as they would like. There are many reasons that can explain this discrepancy.
Patients are an increasingly influential stakeholder within the healthcare industry as more medical information becomes available online than ever before. This independent market research study conducted by MD Analytics takes a closer look at patients in order to better understand their motivations and predict their behaviours within this complex landscape.
Physicians are using social media in their personal and professional lives, especially younger physicians. However, the pharma industry should be aware of barriers to using social media as a means of interacting professionally with physicians, such as the perceived reliability of online information.
In October 2018, the use of recreational cannabis was legalized across Canada. Looking back at the past year, physicians remain divided in their views towards this new legislation, though support skews towards younger GPs. This legislation has impacted the use of prescription treatments and patient visits in a number of key therapeutic areas, though not to the degree that was anticipated 12 months ago.
Measuring customer engagement in pharmaceutical market research can be challenging as physicians usually prefer to not be seen as “associated” with any given pharmaceutical company. However, as demonstrated by our customer engagement syndicated study, it is undeniable that stronger levels of physician engagement exist among pharmaceutical companies which can lead to more positive outcomes for their associated brands.
Real World Evidence (RWE) is a growing area of research that, pivoting from the rigorously controlled standards of randomized controlled trials (RCT), is based on a model driven by real world patient data. Real World Evidence stems primarily from an observational analysis of a sample in a less controlled environment. Focused on the efficacy and outcomes of therapies in a real world setting, RWE provides a unique lens not attainable from traditional clinical trial research.
In the healthcare system, a patient’s journey to optimal care presents many obstacles. There are numerous steps involved from the onset of a medical condition to the moment when satisfactory results are achieved. This healthcare survey seeks to reveal key opportunities within the patient journey that would assist patients along their way and ultimately improve outcomes. Further healthcare market research could also be conducted by disease area to dig deeper into these insights.
Over a 3-day period, MD Analytics surveyed 1,000 Canadians that are responsible for making health-related decisions. It was found that respondents are often choosing to not to see a physician when health-related scenarios arise, citing self-diagnosis or lack of convenience as their key reasons. Respondents are also strongly likely to visit a walk-in clinic instead of their family physician, with convenience again mentioned as the key reason.
Qualitative research can provide a greater understanding of physicians’ attitudes and behaviours than quantitative methodologies, however increased demands on physician time may cause some to refuse participating. Determining the optimal study design and appropriate recruitment techniques can help make physicians more willing to participate.
Biological drugs, protein-based products derived from living cells using biotechnology, have been used since the 1990’s as a treatment option for cancer patients. Since 2009, biosimilar therapies (therapeutically equivalent subsequent entry biologics) have been available in different therapeutic areas in Canada, and are now on the verge of becoming available for use in oncology.
The Canadian Senate recently passed Bill C-46 which will allow for the legal use of recreational cannabis across Canada by Fall 2018. While some physicians anticipate this new legislation will impact their practices with patients electing to try recreational cannabis instead of more traditional prescription medications or medical cannabis, others anticipate increases in patient visits related to dependence and psychotic symptoms.
Dental professionals turn to traditional information channels most often when sourcing information on manufacturer products and continuing education. However, more innovative tools such as online and digital offerings continue to grow in importance, especially among newer dental professionals. Find out how to make sure your future outreach efforts are ready for the next generation of dental professionals.
Traditional in-person continuing health education (CHE) programs remain the most attended format for Canadian physicians practitioners, however preferred sources of CHE vary widely by generation. As educational activities are an important channel to communicate important scientific data about new treatment options, program success will benefit from a tailored approach to CHE delivery.
Biomarkers are molecules found in bodily fluids or tissues (including the tumor tissue). They provide valuable information about the cancer cells and non-cancer cells when analyzing which biomarkers are produced in response to the cancer. By developing a biomarker profile of a patient’s cancer, doctors can recommend the best suited treatment plan for their patient.
With the emergence of Complementary and Alternative Medicine (CAM), prescription options alone are no longer the norm as it pertains to treating a number of medical conditions. Research among N=170 Canadian GPs shows that CAM therapies are not only common practice for many already, but are expected to become even more widely accepted as viable treatment options within the conventional medical community.
The relationship between healthcare providers and sales reps is a balancing act. Managed well they can add value to a GP’s or pharmacist’s practice ultimately impacting product use. However HCPs are often overwhelmed by the demand on their time and as a result may restrict access to their practices to sales reps.